870 reports of this reaction
1.4% of all CAFFEINE CITRATE reports
#9 most reported adverse reaction
ANTI CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE is the #9 most commonly reported adverse reaction for CAFFEINE CITRATE, manufactured by Hikma Pharmaceuticals USA Inc.. There are 870 FDA adverse event reports linking CAFFEINE CITRATE to ANTI CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE. This represents approximately 1.4% of all 60,859 adverse event reports for this drug.
Patients taking CAFFEINE CITRATE who experience anti cyclic citrullinated peptide antibody positive should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANTI CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE is a less commonly reported adverse event for CAFFEINE CITRATE, but still significant enough to appear in the safety profile.
In addition to anti cyclic citrullinated peptide antibody positive, the following adverse reactions have been reported for CAFFEINE CITRATE:
ANTI CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE has been reported as an adverse event in 870 FDA reports for CAFFEINE CITRATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANTI CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE accounts for approximately 1.4% of all adverse event reports for CAFFEINE CITRATE, making it a notable side effect.
If you experience anti cyclic citrullinated peptide antibody positive while taking CAFFEINE CITRATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.